Clinical Trial

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Study acronym: FORTIFY
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-07; most recent amendment 2026-01-24.
Status change: Not Yet Recruiting → Recruiting 2025-10-15
Trial Details
NCT Number NCT06927739
Lead Sponsor Abcentra
Conditions Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
Enrollment 240 participants
Start Date 2025-08-11
Primary Completion 2027-02-08 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-27